Breakthroughs Accelerate in 2026 as Brain-Computer Interface Medical Devices Enter Clinical Era

　　【Pharmaceutical Network Industry DynamicsIn recent years, the innovation ecosystem in China's brain-computer interface field has continued to improve, with technology iteration deepening and the industry as a whole striding toward large-scale application. Among the developments in the brain-computer interface industry, systematic policy support has undoubtedly been the core driver of the industry’s explosive growth opportunities. For instance, in 2025, the Ministry of Industry and Information Technology and six other departments jointly released the "Implementation Opinions on Promoting Innovation and Development in the Brain-Computer Interface Industry," providing a clear roadmap for industrial development.
 

In 2026, "brain-computer interface" was written into the Government Work Report for the first time, identifying it as one of the future industries to be developed. Moreover, at the local level, Beijing, Shanghai, Guangdong, Jiangsu, and other regions have also introduced specialized policies intensively, promoting the coordinated development of the industry in areas such as clinical trials, technological breakthroughs, and production capacity implementation.
 

Under the continuous boost of policies, capital is also highly optimistic about the development in this field, constantly injecting strong momentum into the commercialization process of brain-computer interfaces. For instance, on March 12, Gestalt (Chengdu) Technology Co., Ltd. announced the completion of an angel round of financing worth 150 million RMB; on March 13, Shanghai StairMed Technology Co., Ltd. also announced the completion of a strategic financing round worth 500 million RMB.
 

Currently, under the support of policies and capital, the commercial development of brain-computer interfaces has hit the "acceleration button," with results gradually emerging. On March 13, it was reported that Neuracle's innovative product registration application for an implantable brain-computer interface system for hand motor function compensation had been approved by the National Medical Products Administration. The product is designed for patients with quadriplegia caused by cervical spinal cord injury, assisting in achieving hand grasp functionality through a pneumatic glove device. Utilizing minimally invasive epidural implantation and wireless power supply communication technology, clinical trial results showed that participants experienced significant improvement in hand grasping ability using this product, thereby enhancing their quality of life.
 

As for when the product can be clinically applied, Neuracle stated that it might be prioritized for application in tertiary hospitals that have completed clinical validation. Meanwhile, the company will also consider further expanding the range of indications during the research process.
 

On January 31, BrainCo's attention deficit hyperactivity disorder (ADHD) intervention product "Focusen" medical version officially debuted and was announced to have received approval. The product includes ADHD rehabilitation training software and a prefrontal single-channel EEG collector, both of which have obtained medical device registration certificates, achieving full-chain medical device certification for hardware and software in the brain-computer interface ADHD intervention field.
 

The product adopts a headband-style portable design. Compared with traditional EEG devices, which have complex wiring, up to dozens of electrodes, and high operation thresholds, this product only requires a single-channel electrode to achieve medical-grade precise data collection. Children can wear it independently, significantly reducing the difficulty of use.
 

On January 8, Medlander's independently developed "Brain-Computer Interface (886047) Transcranial Magnetic Stimulator" officially received the medical device (881144) registration certificate issued by the Jiangsu Provincial Drug Administration. After obtaining the registration certificate, this technology will be quickly integrated into the company’s existing software-based hand function training systems, pelvic floor rehabilitation equipment, and other product lines to achieve large-scale application of technological achievements.
 

At the beginning of this year, StairMed has also completed the clinical implantation of its 256-channel wireless high-throughput invasive brain-computer interface system (WRS02) for proposed registration. StairMed announced on its official WeChat account that it plans to initiate large-scale multi-center registration clinical trials by mid-2026 and complete the enrollment and implantation surgeries for nearly 40 patients within the year. Currently, the 256-channel wireless high-throughput invasive brain-computer interface system has entered the "green channel" for innovative medical devices of the National Medical Products Administration (NMPA). Industry insiders expect that the product may be approved for marketing in 2028.
 

　　……
 

In general, the dense breakthroughs in the brain-computer interface field are rapidly verifying the technology's effectiveness and safety while continuously expanding its therapeutic boundaries. In the future, these breakthroughs will form a powerful synergy, driving the industry to accelerate the transition from "technical validation" to "value creation."
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.